Emily Bodnar is ranked #1671 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Emily Bodnar

Q: How accurate are Emily Bodnar's stock ratings?

About 50% of Emily's ratings were profitable over a one-year hold, with an average return of +3.1% per rating, measured by 13Foresight from historical prices.

H.C. Wainwright

Wall Street Analyst

★★★☆☆

#1671

on 13Foresight · ranked by our own returns

50%

Success Rate

+3.1%

Average Return

44 of 88 calls profitable · +3.8% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 50% of Emily Bodnar's ratings turned a profit when each position was held for 1 year — averaging +3.1% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

226 Buy 15 Hold 0 Sell

Emily's Stock Coverage 34 ratings · 2026-08-20

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
JSPR Jasper Therapeutics	Aug 18, 2026	BUY	Buy +3763.9% avg upside 18 analysts	$20.00 2578.84% Upside	-0.4%	·
GNLX Genelux Corp.	Aug 14, 2026	BUY	Strong Buy +577.7% avg upside 7 analysts	$31.00 1056.63% Upside	+0.0%	·
INKT MiNK Therapeutics	Aug 14, 2026	BUY	Strong Buy +90.3% avg upside 6 analysts	$35.00 214.42% Upside	-1.2%	·
IMNN Imunon	Aug 14, 2026	BUY	Strong Buy +824.3% avg upside 11 analysts	$25.00 1482.27% Upside	+0.0%	·
NXTC NextCure	Aug 13, 2026	BUY	Buy +161.2% avg upside 10 analysts	$20.00 195.06% Upside	-0.9%	·
TRAX First Tracks Biotherapeutics Inc	Aug 13, 2026	BUY	Strong Buy +39.9% avg upside 8 analysts	$57.00 25.22% Upside	+0.0%	·
ACRV Acrivon Therapeutics, Inc.	Aug 13, 2026	BUY	Strong Buy +506.5% avg upside 13 analysts	$19.00 694.90% Upside	+5.4%	·
OLMA Olema Pharmaceuticals	Aug 11, 2026	BUY	Strong Buy +245.3% avg upside 16 analysts	$36.00 218.39% Upside	+2.1%	·
NKTX Nkarta	Aug 11, 2026	BUY	Strong Buy +634.0% avg upside 16 analysts	$14.00 451.22% Upside	+0.0%	·
AGEN Agenus	Aug 11, 2026	BUY	Strong Buy +7.6% avg upside 18 analysts	$25.00 202.68% Upside	+7.2%	·
AUTL Autolus Therapeutics	Aug 11, 2026	BUY	Strong Buy +333.2% avg upside 16 analysts	$10.00 293.69% Upside	-7.7%	·
COAG Hemab Therapeutics Holdings, Inc.	Aug 11, 2026	BUY	Strong Buy +3.1% avg upside 5 analysts	$60.00 16.20% Upside	+2.7%	·
SANA Sana Biotechnology	Aug 11, 2026	BUY	Strong Buy +140.8% avg upside 14 analysts	$7.00 70.64% Upside	-6.3%	·
PPBT Purple Biotech	Aug 10, 2026	BUY	Strong Buy +2038.4% avg upside 4 analysts	$17.00 969.24% Upside	+0.0%	·
VTVT vTv Therapeutics	Aug 07, 2026	BUY	Strong Buy +10.6% avg upside 13 analysts	$42.00 27.64% Upside	-14.8%	·
ARTV Artiva Biotherapeutics, Inc.	Aug 07, 2026	BUY	Strong Buy +160.3% avg upside 7 analysts	$35.00 199.07% Upside	+1.6%	·
CNTX Context Therapeutics	Aug 06, 2026	BUY	Strong Buy +983.6% avg upside 12 analysts	$5.00 925.68% Upside	+3.8%	·
RCUS Arcus Biosciences	Aug 06, 2026	BUY	Strong Buy +17.6% avg upside 20 analysts	$45.00 48.25% Upside	+4.1%	·
SABS SAB Biotherapeutics	Aug 06, 2026	BUY	Strong Buy +181.9% avg upside 14 analysts	$10.00 164.61% Upside	-1.8%	·
GERN Geron	Aug 05, 2026	HOLD	Strong Buy +174.8% avg upside 19 analysts	—	-9.8%	·
TGTX TG Therapeutics	Aug 04, 2026	BUY	Strong Buy -13.9% avg upside 20 analysts	$78.00 50.91% Upside	+3.1%	·
AGIO Agios Pharma	Jul 30, 2026	BUY	Strong Buy +77.0% avg upside 29 analysts	$55.00 56.65% Upside	+2.5%	·
NVCR NovoCure	Jul 24, 2026	BUY	Strong Buy +170.9% avg upside 11 analysts	$52.00 185.78% Upside	-4.0%	·
ATOS Atossa Therapeutics	Jun 15, 2026	HOLD	Strong Buy +505.8% avg upside 7 analysts	—	+10.6%	·
SNTI Senti Biosciences	May 15, 2026	BUY	Strong Buy +1814.7% avg upside 7 analysts	$12.00 2491.87% Upside	-55.5%	·
ANAB AnaptysBio	Mar 30, 2026	BUY	Strong Buy +22.3% avg upside 26 analysts	$66.00 11.41% Upside	+58.3%	·
VNDA Vanda	Feb 23, 2026	BUY	Strong Buy +262.0% avg upside 13 analysts	$18.00 223.19% Upside	-36.1%	·
IOBTQ IO Biotech	Nov 17, 2025	HOLD	Buy +252214900.0% avg upside 6 analysts	—	·	·
TSE:BCT BriaCell Therapeutics	Oct 13, 2025	BUY	Strong Buy +920.1% avg upside 1 analyst	$55.59 920.06% Upside	-70.3%	·
FEMY Femasys	Sep 26, 2025	BUY	Strong Buy +2262.5% avg upside 6 analysts	$160.00 5804.05% Upside	·	·
RNAZ TransCode Therapeutics	Apr 29, 2025	HOLD	Buy +14853.2% avg upside 2 analysts	—	-30.6%	·
CNTB Connect Biopharma Holdings	Mar 31, 2025	BUY	Strong Buy +166.7% avg upside 12 analysts	$8.00 225.25% Upside	+376.4%	·
LTRN Lantern Pharma	May 22, 2024	HOLD	Strong Buy +803.6% avg upside 5 analysts	—	-48.1%	·
SQZB SQZ Biotechnologies	Jul 11, 2023	HOLD	Strong Buy +102677.7% avg upside 7 analysts	—	-73.0%	·

🔒 29 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Emily Bodnar — Frequently Asked Questions

How accurate are Emily Bodnar's stock ratings?

Based on the calls 13Foresight could measure, about 50% of Emily's ratings were profitable over a one-year hold, with an average return of +3.1% per rating, or +3.8% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Emily ranked on 13Foresight?

Emily Bodnar is currently ranked #1671 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Emily cover?

Emily most recently has ratings on JSPR, GNLX, INKT, IMNN, NXTC, TRAX, ACRV, OLMA, NKTX, AGEN, AUTL, COAG and 22 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Emily Bodnar

Rating Distribution

Welcome to 13Foresight!